Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering from OSA around the world, it is the most predominant diseases, and can cause life-threatening high blood pressure, heart failure, stroke and other health problems. and life-threatening diseases. “We believe that Vivos’ sleep-specific AireO2 patient management technology represents a significant advancement in how medical and dental professionals will be able to treat sleep disorders,” Vivos’ chairman and CEO Kirk Huntsman in the press release. “Sleep apnea is a serious chronic disease that impacts much more than just sleep — it impacts patients’ quality of life and overall health. With AireO2, we believe that we can make it significantly easier for sleep disorder healthcare providers to manage their growing caseloads and increase the number of patients whom they can treat on any given day. We look forward to continuing the launch of AireO2 as a complement to our existing Billing Intelligence Service for our Vivos Integrated Practices and to actively pursuing AireO2 as a revenue source from other OSA-focused healthcare providers.”
To view the full press release, visit https://ibn.fm/KS9jw
About Vivos Therapeutics Inc.
Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective nonsurgical, noninvasive, nonpharmaceutical, and low-cost solution for patients with sleep disordered breathing (“SDB”), including mild-to-moderate obstructive sleep apnea (“OSA”). The company believes its products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (“CPAP”). For more information about the company, please visit www.VivosLife.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.